Donanemab works by clearing the amyloid protein that builds up in the brains of people with Alzheimer's. Trials suggest it can slow cognitive decline, but not halt the disease.

Credits: envato elements; Author: maksymiv;

Fiona Carragher, director of research at the Alzheimer's Society, a UK charity, said the FDA's approval marked "another step forward" in the fight against dementia.